• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Stock

Quote
anonymous said:
The stock will go > $90 again, just not sustainably for at least the next 12-18 months. We're range-bound < $100 and > $70, with a bias to the downside.

Next year, the dividend will remain flat to a lower than avg increase. There are a number of headwinds beyond what you mentioned that will impact institutional interest in the company. Those include but are not limited to 1) failing to close strategic divestments that would have optimized the balance sheet, 2) missing sales growth targets from recent and future launches and 3) a narrowing margin expansion from an exhausted productivity improvement program.
Click to expand...

> $90 briefly today. A potentially interesting set-up for a re-test of the all-time highs > $
100 just before next week's earnings announcement. However, risk/reward remains limited under current market conditions. $70 target minimum by end July.
 




anonymous said:
> $90 briefly today. A potentially interesting set-up for a re-test of the all-time highs > $
100 just before next week's earnings announcement. However, risk/reward remains limited under current market conditions. $70 target minimum by end July.
Click to expand...

Without all the stim injections into the financial plumbing system in the last quarter, this stock would be in the 60s. Even still, the price is barely holding $80.
 




Top Bottom
Back
Quote